Grifols Biemat (GRFS) - Long-Term Debt to Capital Coefficient
The price action of Grifols, S.A. (GRFS) reflects a current level of 1.36. Grifols, S.A. (GRFS) ensures strict temperature control during the transportation of raw materials across its global supply chain. Business revenues are generated through the sale of albumin and immunoglobulins derived from donor plasma. Its status as a global leader and the complexity of its technical processes allow the issuer to maintain pricing power over its critical medications.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_GRFS_-_Grifols-S.A._-_Long-Term-Debt-to-Capital "GRFS: Grifols Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Grifols, S.A. (GRFS)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:Grifols SA - GRFS
Outsourcing logistics and IT infrastructure allows Grifols, S.A. (GRFS) to optimize capital expenditures, which directly impacts the long-term debt-to-equity ratio. This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, determining the business's degree of leverage and its overall financial stability during periods of tight monetary policy.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Adaptive Biotechnologies Corp (ADPT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com|Long-Term Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PHVS (Pharvaris Corp)|Ratio of Long-Term Indebtedness to Capital AbCellera (ABCL)|TRML - Long-Term Debt to Equity|precigen.com (PGEN) - Long-Term Debt to Equity Ratio|Pharming Group (PHAR) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|Pieris Pharmaceuticals Inc - Long-Term Debt to Capital|Long-Term Indebtedness to Equity Savara Pharma (SVRA)|Rigel Pharmaceuticals (RIGL) - Long-Term Debt to Equity|anaptysbio.com - Long-Term Debt to Capital Coefficient|ATXS (Astria Therapeutics, Inc.) - Long-Term Debt to Capital|enGene Holdings Inc (ENGN) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital RAPT|JBIO: Long-Term Liabilities to Equity|Long-Term Debt to Equity Aclaris Therapeutics ACRS|kyvernatx.com (KYTX) - Long-Term Liabilities to Capital|TLSA - Long-Term Debt to Equity|CABA: Long-Term Debt to Equity|Ventyx Bio (VTYX) - Long-Term Debt to Equity|THTX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio AVTX|ELDN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Agenus Inc. (AGEN)|Ratio of Long-Term Indebtedness to Capital Climb Bio Inc.|Zura Bio Limited - Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital aTyr Pharmaceuticals (ATYR)|Adagene Corp - Long-Term Debt to Capital|IMA - Long-Term Debt to Capital|STTK (shattucklabs.com) - Long-Term Debt to Equity Ratio|EQ - Ratio of Long-Term Indebtedness to Capital|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|IMUX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Atara Biotherapeutics (ATRA)|IFRX (inflarx.de) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|ACET (Adicet Bio Inc.) - Long-Term Liabilities to Equity|CELU - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital INmune Bio Corporation INMB|Barinthus Biotherapeutics (BRNS) - Long-Term Debt to Equity|Long-Term Liabilities to Equity KZR (kezarlifesciences.com)|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|AKTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ENLV|Long-Term Debt to Capital q32bio.com (QTTB)|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|Long-Term Debt to Capital Coefficient EDSA|IBIO - Long-Term Debt to Equity|Carisma Therapeutics (CARM) - Long-Term Debt to Equity Ratio|XTLB: Long-Term Debt to Capital|Bolt Biotherapeutics, Inc. (BOLT) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio HCWB|APVO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital AIM|Ratio of Long-Term Indebtedness to Capital aditxt.com|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX - Long-Term Debt to Equity Ratio|HIND - Long-Term Debt to Equity|revbiosciences.com (REVB) - Long-Term Debt to Equity Ratio|INDP (Indaptus Therapeutics, Inc.) - Long-Term Debt to Equity Ratio|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc|Long-Term Debt to Capital Ratio AFMD (Affimed Therapeutics)|Long-Term Debt to Capital ALLK|HOOK - Long-Term Liabilities to Capital|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Indebtedness to Equity iTeos Therapeutics Inc|OCEA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|THRD: Long-Term Debt to Capital